Treatment choice for localized prostate cancer is preference sensitive given that several medically viable and effective treatment options are available, each with specific risks and benefits. We present the development and effectiveness of our PreProCare preference assessment instrument to assess the association between value markers (utility levels) and treatment choice in localized prostate cancer patients. We observed that preference assessment intervention helped prostate cancer patients reveal their preferences, leading to better alignment with treatment decision.
